ADAPTATION
TO A CHANGING ENVIRONMENT.

The 1997 Bemitil / phenibut work addresses exertion, protective equipment and overheating. The companion report specifies 30 ± 1°C and several comparator arms. The abstracts do not provide a Bemitil-specific percentage improvement or complete allocation details. PMIDs 9162292 ↗ / 9235216 ↗.

RU2704126C2 reports mean running time of 41.66 versus 27.69 minutes in male mice. The percentage is calculated from those means. Small groups, inconsistent Bemitil n=8/n=9 reporting and patent-example status make independent replication essential.

A 2009 report studies citoflavin, reamberin, hypoxen and mexidol in healthy volunteers aged 20–24 under overheating, cold and hypobaric hypoxia. The abstract describes environment-dependent effects. It does not test Bemitil. PMID 20095399 ↗.

Our bet is that actoprotectors and meteoadaptogenic drugs can become a frontier beyond peptides. That is an investment thesis. Each compound needs its own mechanism, controlled outcome and safety package; class membership does not establish efficacy.

Start with one controlled heat-performance question and the associated molecular response. Extend to cold, oxygen availability or changing climate only through separately designed studies. No present weather-sensitivity treatment or proven all-climate protection is claimed.